SCHEMBL1824997

SCHEMBL1824997

Cc1ccc(S(=O)(=O)Oc2cccc(C(CC(=O)OCc3ccccc3)C(N)C(=O)OCC3c4ccccc4-c4ccccc43)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
P2RX7 Q99572 11/20 0.37
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SLC15A1 P46059 1/20 0.34
CASP3 P42574 2/20 0.33
MAPT P10636 1/20 0.33
DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1826186 0.94 KMT2A (0.37) KMT2ASMN1; SMN2SLC15A1CASP3
SCHEMBL1825016 0.92 DHODH (0.35) LMNAKMT2ACASP3MAPTDHODH
SCHEMBL1824683 0.91 P2RX7 (0.42) LMNAP2RX7SMN1; SMN2SLC15A1MAPT
SCHEMBL1822423 0.91 CASP3 (0.35) CASP3MAPTDHODH
SCHEMBL1827318 0.90 LMNA (0.45) LMNAP2RX7KMT2ASMN1; SMN2SLC15A1
SCHEMBL1821706 0.89 GPR17 (0.34) LMNAKMT2ACASP3MAPTDHODH
SCHEMBL1823539 0.89 P2RX7 (0.39) LMNAP2RX7KMT2ASMN1; SMN2MAPT
SCHEMBL1824970 0.89 CASP3 (0.37) KMT2ASMN1; SMN2CASP3
SCHEMBL3574268 0.89 CASP3 (0.38) KMT2ASMN1; SMN2SLC15A1CASP3
SCHEMBL1823288 0.88 P2RX7 (0.33) P2RX7KMT2ACASP3MAPTDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 LMNA 1802/4885P2RX7 3606/4885KMT2A 1068/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 LMNA 1130/4885P2RX7 2747/4885KMT2A 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.